Research Programs-Developmental Therapeutics

发展治疗学研究计划（DTP）是一个历史悠久的跨学科研究 该项目成立于1974年，是耶鲁大学癌症研究所的第一个研究项目。 中心（YCC）。该计划有36名成员，代表13个学术部门的学校， 医学院和耶鲁大学的两个学院。该计划的领导人是Yung-Chi Cheng博士。和 Edward Chu，医学博士，他们是发育治疗学和癌症药物领域的顶尖专家， 发展他们招募、培养并指导对癌症感兴趣的研究人员 药理学和发育治疗学。它们促进和便利方案间和方案内的 合作，并确定该研究计划的成员可以从 YCC的共享资源。该计划的主要重点是在癌症和病毒领域（那些 与癌症相关或在癌症病因学中起重要作用的那些）化疗。 具体而言，《方案》重点关注以下几个主要侦查领域：（1）目标识别， 验证和表征;（2）分子/生化药理学表征 抗癌和抗病毒化合物以及细胞耐药机制的表征;（3） 药物发现/开发;和（4）临床试验设计和开发。成员的选择基于 他们的科学证书，必须集中在基础，转化和临床癌症研究。高 优先考虑那些深深致力于该计划所提出的目标的成员， 重点发展广泛的方案内互动以及强有力的互动/协作 其他YCC研究项目。特别是，已作出重大努力，发展一个强有力的 开发新型抗癌药物和新的联合治疗方案的转化临床计划 治疗人类癌症。最后，发展治疗学项目的成员是 积极鼓励青年商会广泛利用共享资源。 对这一组的同行审查供资支助总额约为每年570万美元的直接费用（870万美元 总费用为289万美元，其中直接费用为289万美元（总费用为449万美元）， 研究所（NCI）。此外，每年从非同行收到近230万美元的直接费用（总费用为280万美元） 审查赠款机制。在上一个赠款期间，该计划的成员发表了 697篇癌症相关论文，其中10%是项目内论文，12%是项目间论文。

The Developmental Therapeutics Research Program (DTP) is a long-standing interdisciplinary research program that was established in 1974, and this program was the first research program of the Yale Cancer Center (YCC). This program has 36 members representing 13 academic departments of the School of Medicine and 2 schools of Yale University. The leaders of the Program are Yung-Chi Cheng, Ph.D. and Edward Chu, M.D., who are leading experts in the field of developmental therapeutics and cancer drug development. They recruit, develop, and provide guidance to investigators interested in cancer pharmacology and developmental therapeutics. They foster and facilitate inter- and intra-programmatic collaborations and identify ways in which the membership of this research program can benefit from the shared resources of the YCC. The major focus of the Program is in the area of cancer and viral (those associated with cancer or those playing an important role in the etiology of cancer) chemotherapy. Specifically, the Program focuses on the following major areas of investigation: (1) target identification, validation, and characterization; (2) characterization of the molecular/biochemical pharmacology of anticancer and antiviral compounds and characterization of the mechanisms of cellular drug resistance; (3) drug discovery/development; and (4) clinical trial design and development. Members are selected based on their scientific credentials, which must focus on basic, translational, and clinical cancer research. A high priority is placed on members who are deeply committed to the goals set forth by the Program and who focus on developing extensive intra-programmatic interactions as well as strong interactions/collaborations with other YCC research programs. In particular, significant efforts have been placed on developing a strong translational clinical program of developing novel anticancer agents and new combination regimens for the treatment of human cancers. Finally, the membership of the Developmental Therapeutics Program is actively encouraged to make extensive use of the YCC shared resources. Total peer-reviewed funding support of this group is approximately $5.7 million direct costs annually ($8.7 million total costs), of which $2.89 million direct costs ($4.49 million total costs) is from the National Cancer Institute (NCI). In addition, nearly a $2.3 million direct cost ($2.8 total costs) is received annually from nonpeer reviewed granting mechanisms. During the previous grant period, members of this program published 697 cancer-related papers, of which 10% were intra-programmatic and 12% inter-programmatic.